Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF). Data Sources: Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular. The references of relevant articles were reviewed to identify additional citations. Study Selection and Data Extraction: Clinical trials were limited to the English language and human trials. In all, 18 trials explored the use of GLP-1 RAs in the treatment of cardiac disorders in patients with and without diabetes mellitus. Data Synthesis: Of the 18 trials reviewed, 11 trials studied the impact of GLP-1 RAs in MI. All showed a significant beneficial effect on various cardiac parameters. Favorable outcome improvements included myocardial blood flow, left ventricular (LV) function, and MI size. Seven trials reviewed the use of GLP-1 RAs in the treatment of HF. Three trials showed significant improvements in LV ejection fraction, cardiac index, and peak oxygen consumption. Conclusions: Limited data suggest that GLP-1 RAs may be effective for the treatment of cardiac disorders in patients with and without diabetes mellitus. These studies suggest that GLP-1 RAs may have potential pleiotropic beneficial effects in patients with cardiovascular disease beyond their role in managing diabetes. These medications may be cardioprotective after a MI but are less promising in HF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“One mechanism of action of GLP-1 RAs in type 2 diabetes involves binding to receptors in the β cells, which leads to stimulation of insulin secretion.(1) Current GLP-1 RAs include exenatide (Byetta, Bydureon), dulaglutide (Trulicity), albiglutide (Tanzeum), liraglutide (Victoza), and the recently approved lixisenatide…”
BackgroundGrundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Diabetes and cardiovascular disease
Howard, B. V., & Magee, M. F. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0046-8 · Cited by 1,381
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 3×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundBergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Thorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550 · cited 4×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodInfluentialAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., & Trautmann, M. (2007) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 437
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Tracy, M. (1999) · Biomaterials · doi:10.1016/s0142-9612(99)00002-2 · Cited by 411
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Eckel, R. H., Barouch, W. W., & Ershow, A. G. (2002) · Circulation · doi:10.1161/01.cir.0000017823.53114.4c · Cited by 258
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Woo, J. S., Kim, W., Ha, S. J., Kim, J. B., Kim, S.-J., Kim, W.-S., Seon, H. J., & Kim, K. S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301586 · Cited by 223 · cited 3×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodEffect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215
Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E., Helqvist, S., Saunamäki, K., Terkelsen, C. J., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.968388 · Cited by 210 · cited 3×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodMalm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
Halbirk, M., Nørrelund, H., Møller, N., Holst, J. J., Schmitz, O., Nielsen, R., Nielsen-Kudsk, J. E., Nielsen, S. S., Nielsen, T. T., Eiskjær, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00930.2009 · Cited by 165 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundLepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.01.008 · Cited by 165 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundThe Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & Chilton, R. J. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 136 · cited 2×
“The first one is that GLP-1 RAs may improve cardiac function by increasing glucose uptake, cyclic adenosine monophosphate release, and cyclic guanosine monophosphate release, which lead to vasodilation and can improve coronary flow and left ventricular (LV) pressure.(3) Another theory is that as HF progresses, the car…”
BackgroundSimonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133
Chen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 123 · cited 5×
“Each trial measured different cardiac parameters and used varying methods to measure the parameters.(4-14) Finally, some studies used diabetes as an inclusion criterion, whereas in other studies it was an exclusion criterion.”
BackgroundMethodInfluentialThrainsdottir, I., Malmberg, K., Olsson, A., Gutniak, M., & Rydén, L. (2004) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2004.005 · Cited by 120 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundRead, P. A., Hoole, S. P., White, P. A., Khan, F. Z., O'Sullivan, M., West, N. E. J., & Dutka, D. P. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.960476 · Cited by 119 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodNathanson, D., Ullman, B., Löfström, U., HEDMAN, A. G., Frick, M., Sjöholm, Å., & Nyström, T. (2012) · Diabetologia · doi:10.1007/s00125-011-2440-x · Cited by 103 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundClarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 100
Scheidt-Nave, C., Barrett-Connor, E., & Wingard, D. L. (1990) · Circulation · doi:10.1161/01.cir.81.3.899 · Cited by 97
Chen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 89 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodDamholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M., & Zdravkovic, M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288215 · Cited by 82
Gejl, M., Søndergaard, H. M., Stecher, C., Bibby, B. M., Møller, N., Bøtker, H. E., Hansen, S. B., Gjedde, A., Rungby, J., & Brock, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3456 · Cited by 78 · cited 3×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodDokken, B. B., La Bonte, L. R., Davis-Gorman, G., Teachey, M. K., Seaver, N., & McDonagh, P. F. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1271777 · Cited by 71 · cited 1×
“A rat study showed that GLP-1 decreases the surface expression of CD11b on PMNs, leading to decreased reperfusion injury.(24) Literature Search A search of human trials in the English-language literature was conducted through MEDLINE (1946 to May 2016) using OVID, and EBSCOhost and Exerpta Medica (1980May 2016) using…”
MethodActions of Gila monster venom on dispersed acini from guinea pig pancreas
Raufman, J. P., Jensen, R. T., Sutliff, V. E., Pisano, J. J., & Gardner, J. D. (1982) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1982.242.5.g470 · Cited by 53
Chen, W. R., Tian, F., Chen, Y. D., Wang, J., Yang, J. J., Wang, Z. F., Wang, J. D., & Ning, Q. X. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.009 · Cited by 49 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
BackgroundMethodDifferential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 47
Margulies, K. B., Anstrom, K. J., Hernandez, A. F., Redfield, M. M., Shah, M. R., Braunwald, E., & Cappola, T. P. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.000346 · Cited by 46 · cited 6×
“It was found that 18 trials4-21 explored the use of GLP in MI and HF.”
BackgroundInfluentialQa’aty, N., Wang, Y., Wang, A., Mao, S., Vincent, M. L., Husain, M., & Hinek, A. (2014) · Endocrinology · doi:10.1210/en.2014-1519 · Cited by 27 · cited 12×
“Chen et al12 evaluated 92 patients with and without diabetes who were admitted to a Chinese general hospital with a STEMI.”
BackgroundInfluentialClinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
Aroda, V. R., & DeYoung, M. B. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2479 · Cited by 27
Nozue, T., Yamada, M., Tsunoda, T., Katoh, H., Ito, S., Iwaki, T., & Michishita, I. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0734-5 · Cited by 25
Papworth Hospital NHS Foundation Trust
Feldman, H., Goldacre, B. M., DeVito, N., & Bacon, S. (2017) · Figshare · doi:10.6084/m9.figshare.5472436 · Cited by 11
Metabolic Effects of Short-term GLP-1 Treatment in Insulin Resistant Heart Failure Patients
Nielsen, R. R., Wiggers, H., Halbirk, M., Bøtker, H. E., Holst, J. J., Schmitz, O., Frandsen, E., Nielsen, S., Møller, N., & Nørrelund, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1304605 · Cited by 8 · cited 2×
“Studies have been conducted to determine if GLP-1 RAs may be useful in the treatment of cardiac disorders, such as heart failure (HF) and myocardial infarction (MI).(4-21) Two main theories about the mechanism of action of GLP-1 RAs in HF have been proposed.”
Background
Research works printed but not linked: 1
- Margulies KB, Paper presented at: American Heart Association 2015 Scientific Sessions
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“GLP-1R activation affects renal function [83] and has pleiotropic cardioprotective effects [84].”
BackgroundPenna, C. R. R., Andreadou, I., Aragno, M., Beauloye, C., Bertrand, L., Lazou, A., Falcão‐Pires, I., Bell, R., Zuurbier, C. J., Pagliaro, P., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14993 · Cited by 114
“These medications may be cardioprotective after an AMI but are less promising in heart failure (HF) et al., 2016; reviewed in Wroge and Williams, 2016).”
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Recio, C., Μaione, F., Iqbal, A. J., Mascolo, N., & Feo, V. D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00526 · Cited by 123
“Interestingly, besides regulation of glucose homeostasis, GLP-1 mimetic peptides have also been shown to exert cardioprotective effects in cardiovascular-related death, nonfatal MI, and non-fatal stroke (Advani et al., 2013; Wroge and Williams, 2016).”
BackgroundCardiac metabolism — A promising therapeutic target for heart failure
Noordali, H., Loudon, B. L., Frenneaux, M. P., & Madhani, M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.001 · Cited by 104
Metadata
- Authors
- Wroge, J., & Williams, N. T.
- Affiliations
- Southwestern Oklahoma State University (US)
- Corresponding author
- Williams, Nancy Toedter
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2016-08-20
- Volume
- 50
- Issue
- 12
- Pages
- 1041-1050
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2509831471
- Semantic Scholar
- 41b455ea68de346dbda5dcf1481cf6fe09b1affd
- Cited by
- 17
- References
- 64
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 5 · 2016: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- GLP-1 receptor agonists, myocardial infarction, heart failure, cardioprotection, exenatide, liraglutide, dulaglutide, albiglutide, left ventricular function, diabetes mellitus, cardiovascular disease
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Peptides, Recombinant Fusion Proteins, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.